Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis

JAMA

Volumn 309, Issue 21, 2013, Pages 2232-2239

  Peljto, Anna L ^a   Zhang, Yingze ^a   Fingerlin, Tasha E ^a   Shwu Fan, Ma ^d   Garcia, Joe G N ^e   Richards, Thomas J ^f   Silveira, Lori J ^c   Lindell, Kathleen O ^f   Steele, Mark P ^g   Loyd, James E ^g   Gibson, Kevin F ^f   Seibold, Max A ^c   Brown, Kevin K ^c   Talbert, Janet L ^c   Markin, Cheryl ^g   Kossen, Karl ^h   Seiwert, Scott D ^h   Murphy, Elissa ^b   Noth, Imre ^d   Schwarz, Marvin I ^b   Kaminski, Naftali ^f   Schwartz, David A ^b,c   more..

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h InterMune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA1B INTERFERON; MATRILYSIN; MUCIN 5B;

AGE; AGED; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENDER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUC5B GENE; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 84878600828     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.5827     Document Type: Article

References (29)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med . 2001;345(7):517-525. (Pubitemid 32758505)
2. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One. 2007;2(5):e482.
3. Martinez FJ, Safrin S, Weycker D, et al IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med . 2005;142(12 pt 1):963-967.
4. Collard HR, Moore BB, Flaherty KR, et al Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636-643. (Pubitemid 47503070)
5. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med . 2001;164(7):1171-1181. (Pubitemid 33052246)
6. Prasse A, Probst C, Bargagli E, et al. Serum CCchemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717-723.
7. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162(3 pt 1):1109-1114.
8. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185(1):67-76.
9. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med . 2007;356(13):1317-1326. (Pubitemid 46513297)
10. Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344(8):573-579. (Pubitemid 32167871)
11. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84(1):52-59.
12. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med . 2011;364(16):1503-1512.
13. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med. 2011;364(16):1576-1577.
14. King TE Jr, Albera C, Bradford WZ, et al INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet . 2009;374(9685):222-228.
15. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics . 2005;61(1):92-105. (Pubitemid 40380968)
16. Cosgrove GP, Groshong SD, Peljto AL, et al. The MUC5B promoter polymorphism is associated with a less severe pathological form of familial interstitial pneumonia (FIP) [abstract]. Am J Respir Crit Care Med. 2012;185:A6865.
17. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax. 2013;68(5):436-441. doi:10.1136/thoraxjnl-2012-201786.
18. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med . 2003;167(7):962-969. (Pubitemid 36408161)
19. Ley B, Ryerson CJ, Vittinghoff E, et al. A multi-dimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med . 2012;156(10):684-691.
20. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184(12):1382-1389.
21. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):830-836.
22. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538-542. (Pubitemid 37088595)
23. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543-548. (Pubitemid 37088596)
24. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet . 2011;378(9807):1949-1961.
25. Raghu G. Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. Lancet. 2012;380(9842):699-701.
26. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis [published online April 14, 2013]. Nat Genet. doi: 10.1038/ng.2609.
27. Wittke-Thompson JK, Pluzhnikov A, Cox NJ. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet . 2005;76(6):967-986. (Pubitemid 40705433)
28. Boon K, Bailey NW, Yang J, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One. 2009;4(4):e5134.
29. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med . 2008;5(4):e93.